Healthcare / BiotechnologyKOSDAQ
$2765.00
-65.00 (-2.30%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-18.1B · quality 74.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$381.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-22.0%
↓Gross Margin
57.3%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+22.5%
FCF CAGR
—
FCF margin
-284.2%
FCF / Net income
1.08x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.23B · net income $-24.19B · FCF $-26.22B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.23B | $9.23B | $3.93B | $3.94B | $5.01B |
| Net Income | $-24.19B | $-24.19B | $-26.53B | $-20.37B | $-24.59B |
| EBITDA | $-22.11B | $-22.11B | $-23.69B | $-17.35B | $-20.62B |
| EPS | -175.00 | -175.00 | -220.00 | -179.83 | -217.07 |
| Gross Margin | 57.3% | 57.3% | 18.5% | 37.0% | 29.6% |
| Operating Margin | -285.3% | -285.3% | -714.5% | -541.8% | -488.2% |
| Net Margin | -262.2% | -262.2% | -675.5% | -517.0% | -490.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.08 | 0.17 | 0.19 |
| Current Ratio | 15.81 | 15.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-26.22B | $-26.22B | $-18.06B | $-17.38B | $-41.59B |
| Returns | |||||
| ROE | -22.0% | -22.0% | -20.1% | -35.5% | -31.2% |
| Valuation | |||||
| P/B | 3.47 | 3.47 | 2.34 | 11.38 | 9.62 |
| Growth & Yield | |||||
| Revenue Growth | 134.9% | 134.9% | -0.3% | -21.4% | — |
| EPS Growth | 20.5% | 20.5% | -22.3% | 17.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-220.00 → -175.00
Residual
-11.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.